Pub Date : 2021-04-03DOI: 10.21608/RESONCOL.2021.51731.1128
Noha Eisa, A. Alshehri, M. Assiri
Chronic lymphocytic leukemia (CLL) typically occurs in the elderly and has a highly variable clinical course. Infectious complications have been known to be a major cause of morbidity and mortality in CLL patients. The management of hematological malignancies, including CLL, during the COVID-19 pandemic is challenging. Here we describe two patients with CLL who got infected with SARS-COV-2 as confirmed by positive nasopharyngeal swab PCR. The 1st patient, who was receiving treatment for CLL-associated autoimmune hemolytic anemia, was hospitalized with mild COVID-19 symptoms. The 2nd patient, who was on active treatment for CLL, had asymptomatic COVID-19 infection and was not hospitalized. Both patients recovered from COVID-19 without related complications.
{"title":"COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia: Report of Two Cases and Literature Review","authors":"Noha Eisa, A. Alshehri, M. Assiri","doi":"10.21608/RESONCOL.2021.51731.1128","DOIUrl":"https://doi.org/10.21608/RESONCOL.2021.51731.1128","url":null,"abstract":"Chronic lymphocytic leukemia (CLL) typically occurs in the elderly and has a highly variable clinical course. Infectious complications have been known to be a major cause of morbidity and mortality in CLL patients. The management of hematological malignancies, including CLL, during the COVID-19 pandemic is challenging. Here we describe two patients with CLL who got infected with SARS-COV-2 as confirmed by positive nasopharyngeal swab PCR. The 1st patient, who was receiving treatment for CLL-associated autoimmune hemolytic anemia, was hospitalized with mild COVID-19 symptoms. The 2nd patient, who was on active treatment for CLL, had asymptomatic COVID-19 infection and was not hospitalized. Both patients recovered from COVID-19 without related complications.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47499961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-01DOI: 10.21608/RESONCOL.2019.12451.1077
E. Saad, K. Elshahat, Hussein M. Metwally
Background: Pelvic bone marrow (PBM) preservation is one of the factors that should be taken into consideration while choosing a technique for radiotherapy of pelvic malignancies. Aim: To dosimetrically compare between volumetric-modulated arc therapy (VMAT) and intensity-modulated radiotherapy (IMRT) in PBM preservation in radical treatment of high-risk prostate cancer. Methods: In 26 patients with high-risk prostatic carcinoma, dual arc VMAT and 7 fields IMRT plans were generated. In every patient, two targets were defined, clinical target volume (CTV) including the prostate and seminal vesicles (CTV-PSV) and CTV including pelvic lymph nodes (CTV-LN). The organs at risk delineated were the rectum, urinary bladder, small intestine, bulb of the penis, femoral heads bilaterally and PBM. The dose prescribed to the CTV-PSV was 76 Gy in 38 fractions given over 7.5 weeks and the dose to CTV-LN was 54 Gy in 38 fractions given over 7.5 weeks. Planning target volume (PTV) was created from the CTV with a margin of 5 mm in all direction. For assessment of PBM dose, V10, V20, V30, V40, V50 and mean dose were calculated. The dose volume histogram of PTV and PBM for both techniques was compared. Results: The mean dose of PTV 54 Gy was achieved in both techniques adequately with better sparing of organs at risk with the VAMT technique. The mean dose for PBM in the VMAT technique was significantly less than that in the IMRT (21.7 Gy vs. 25.8 Gy, respectively; p < 0.001). The significant differences in PBM doses were in the range of 20 Gy to 40 Gy. Conclusion: In radical treatment of prostate cancer, VMAT technique can offer comparable conformality to IMRT with better PBM preservation. Awareness of PBM delineation and reduction of its doses using VMAT can help to decrease the hematological toxicity.
{"title":"Dosimetric Comparison of Pelvic Bone Marrow Preservation between Volumetric-Modulated Arc Therapy and Intensity-Modulated Radiotherapy in Radical Radiotherapy of High-Risk Prostate Cancer","authors":"E. Saad, K. Elshahat, Hussein M. Metwally","doi":"10.21608/RESONCOL.2019.12451.1077","DOIUrl":"https://doi.org/10.21608/RESONCOL.2019.12451.1077","url":null,"abstract":"Background: Pelvic bone marrow (PBM) preservation is one of the factors that should be taken into consideration while choosing a technique for radiotherapy of pelvic malignancies. \u0000Aim: To dosimetrically compare between volumetric-modulated arc therapy (VMAT) and intensity-modulated radiotherapy (IMRT) in PBM preservation in radical treatment of high-risk prostate cancer. \u0000Methods: In 26 patients with high-risk prostatic carcinoma, dual arc VMAT and 7 fields IMRT plans were generated. In every patient, two targets were defined, clinical target volume (CTV) including the prostate and seminal vesicles (CTV-PSV) and CTV including pelvic lymph nodes (CTV-LN). The organs at risk delineated were the rectum, urinary bladder, small intestine, bulb of the penis, femoral heads bilaterally and PBM. The dose prescribed to the CTV-PSV was 76 Gy in 38 fractions given over 7.5 weeks and the dose to CTV-LN was 54 Gy in 38 fractions given over 7.5 weeks. Planning target volume (PTV) was created from the CTV with a margin of 5 mm in all direction. For assessment of PBM dose, V10, V20, V30, V40, V50 and mean dose were calculated. The dose volume histogram of PTV and PBM for both techniques was compared. \u0000Results: The mean dose of PTV 54 Gy was achieved in both techniques adequately with better sparing of organs at risk with the VAMT technique. The mean dose for PBM in the VMAT technique was significantly less than that in the IMRT (21.7 Gy vs. 25.8 Gy, respectively; p < 0.001). The significant differences in PBM doses were in the range of 20 Gy to 40 Gy. \u0000Conclusion: In radical treatment of prostate cancer, VMAT technique can offer comparable conformality to IMRT with better PBM preservation. Awareness of PBM delineation and reduction of its doses using VMAT can help to decrease the hematological toxicity.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45006294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-01DOI: 10.21608/RESONCOL.2019.12516.1078
Mai Atef, E. Sheikh, M. Ellithy, K. Naguib, Amr Shafik Tawfik
Background: Hypofractionated radiotherapy in early breast cancer yields equivalent or better outcome in terms of efficacy, toxicity, cosmesis and cost-effectiveness. However, its role in node-positive breast cancer is less clear. Aim: To compare between adjuvant conventional and hypofractionated radiotherapy in node-positive breast cancer. Methods: Prospective pilot study of 66 node-positive breast cancer patients recruited over 1 year in a single institution. Patients were randomized to receive adjuvant conventional radiotherapy 200 cGy x 25 fractions with 200 cGy x 5 fractions boost to the tumor bed in case of breast conservation (control arm) or hypofractionated radiotherapy 266 cGy x 16 fractions with 266 cGy x 4 fractions boost to the tumor bed in case of breast conservation (intervention arm). The end points were disease-free survival, cosmetic outcome, ipsilateral arm lymphedema and acute skin reactions. Results: Disease-free survival did not differ significantly between the two treatment arms (p = 0.6) and the 2-year disease-free survival rate was 87% and 89% in the hypofractionated and conventional arms. The rate of excellent/good cosmetic score was higher in the hypofractionated arm than the conventional as rated by patients (71% vs. 46%, p = 0.182) and physicians (29% vs. 8%, p = 0.32). Hypofractionation, when compared to conventional fractionation, was associated with less arm lymphedema (22% vs. 40%, p = 0.149), dry desquamation (28% vs. 53%, p = 0.04), skin darkness (0% vs. 15%, p = 0.054) and wet desquamation (16% vs. 21%, p = 0.601). Conclusion: Hypofractionated adjuvant radiotherapy in node-positive breast cancer patients is equivalent to conventional fractionation as regards disease-free survival, cosmetic outcome and arm lymphedema with less early skin reactions.
背景:低分割放疗在早期乳腺癌的疗效、毒性、美观性和成本效益方面具有同等或更好的结果。然而，它在淋巴结阳性乳腺癌中的作用尚不清楚。目的:比较常规辅助放疗与低分割放疗对淋巴结阳性乳腺癌的治疗效果。方法:前瞻性试点研究，66名淋巴结阳性乳腺癌患者在一个机构招募超过1年。患者随机接受常规辅助放疗，保乳组200 cGy × 25分次，200 cGy × 5分次强化至肿瘤床(对照组);保乳组266 cGy × 16分次，266 cGy × 4分次强化至肿瘤床(干预组)。终点为无病生存期、美容效果、同侧手臂淋巴水肿和急性皮肤反应。结果:两组无病生存率无显著差异(p = 0.6)，低分割组和常规组的2年无病生存率分别为87%和89%。患者(71% vs. 46%， p = 0.182)和医生(29% vs. 8%， p = 0.32)对低分割组美容评分优良率均高于常规组。与常规分离术相比，低分离术与手臂淋巴水肿减少(22%对40%，p = 0.149)、干脱屑(28%对53%，p = 0.04)、皮肤暗沉(0%对15%，p = 0.054)和湿脱屑(16%对21%，p = 0.601)相关。结论:低分割辅助放疗在淋巴结阳性乳腺癌患者的无病生存率、美容效果和上臂淋巴水肿方面与常规分割相当，且早期皮肤反应较少。
{"title":"Randomized Prospective Study Comparing Conventional Versus Hypofractionated Adjuvant Radiotherapy in Node-Positive Breast Cancer","authors":"Mai Atef, E. Sheikh, M. Ellithy, K. Naguib, Amr Shafik Tawfik","doi":"10.21608/RESONCOL.2019.12516.1078","DOIUrl":"https://doi.org/10.21608/RESONCOL.2019.12516.1078","url":null,"abstract":"Background: Hypofractionated radiotherapy in early breast cancer yields equivalent or better outcome in terms of efficacy, toxicity, cosmesis and cost-effectiveness. However, its role in node-positive breast cancer is less clear. \u0000Aim: To compare between adjuvant conventional and hypofractionated radiotherapy in node-positive breast cancer. \u0000Methods: Prospective pilot study of 66 node-positive breast cancer patients recruited over 1 year in a single institution. Patients were randomized to receive adjuvant conventional radiotherapy 200 cGy x 25 fractions with 200 cGy x 5 fractions boost to the tumor bed in case of breast conservation (control arm) or hypofractionated radiotherapy 266 cGy x 16 fractions with 266 cGy x 4 fractions boost to the tumor bed in case of breast conservation (intervention arm). The end points were disease-free survival, cosmetic outcome, ipsilateral arm lymphedema and acute skin reactions. \u0000Results: Disease-free survival did not differ significantly between the two treatment arms (p = 0.6) and the 2-year disease-free survival rate was 87% and 89% in the hypofractionated and conventional arms. The rate of excellent/good cosmetic score was higher in the hypofractionated arm than the conventional as rated by patients (71% vs. 46%, p = 0.182) and physicians (29% vs. 8%, p = 0.32). Hypofractionation, when compared to conventional fractionation, was associated with less arm lymphedema (22% vs. 40%, p = 0.149), dry desquamation (28% vs. 53%, p = 0.04), skin darkness (0% vs. 15%, p = 0.054) and wet desquamation (16% vs. 21%, p = 0.601). \u0000Conclusion: Hypofractionated adjuvant radiotherapy in node-positive breast cancer patients is equivalent to conventional fractionation as regards disease-free survival, cosmetic outcome and arm lymphedema with less early skin reactions.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43605464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-01DOI: 10.21608/RESONCOL.2019.11625.1076
W. Makar
Background: Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is characterized by being more aggressive, presentation in younger age, and higher response rate to chemotherapy. It is more likely to recur and to metastasize early. Methods: Retrospective review of the medical records of TNBC patients treated in a single Egyptian cancer center during a 4-year period. Results: Sixty-five patients were included. Forty-six percent of patients were < 50 years old and 22% had a positive family history. Ten (15%) patients were metastatic at presentation. Modified radical mastectomy was performed in 42% of patients and adjuvant chemotherapy was administered in 55% of them. Relapse occurred in 12 (22%) out of 55 patients who had no distant metastasis at presentation (M0). The overall survival rate of M0 patients at 12, 24 and 36 months was 96%, 91% and 88%; respectively. The disease-free survival rate of M0 patients at 12, 24 and 36 months was 90%, 81% and 71%; respectively. Conclusion: In Egyptian female patients,TNBC is an aggressive subtype of breast cancer that occurs at younger age. Frequently, it is of high grade and presents in an advanced stage.
{"title":"Clinicopathological Characteristics and Survival of Triple-Negative Breast Cancer Patients: A single Institution Study from Egypt","authors":"W. Makar","doi":"10.21608/RESONCOL.2019.11625.1076","DOIUrl":"https://doi.org/10.21608/RESONCOL.2019.11625.1076","url":null,"abstract":"Background: Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is characterized by being more aggressive, presentation in younger age, and higher response rate to chemotherapy. It is more likely to recur and to metastasize early. Methods: Retrospective review of the medical records of TNBC patients treated in a single Egyptian cancer center during a 4-year period. Results: Sixty-five patients were included. Forty-six percent of patients were < 50 years old and 22% had a positive family history. Ten (15%) patients were metastatic at presentation. Modified radical mastectomy was performed in 42% of patients and adjuvant chemotherapy was administered in 55% of them. Relapse occurred in 12 (22%) out of 55 patients who had no distant metastasis at presentation (M0). The overall survival rate of M0 patients at 12, 24 and 36 months was 96%, 91% and 88%; respectively. The disease-free survival rate of M0 patients at 12, 24 and 36 months was 90%, 81% and 71%; respectively. Conclusion: In Egyptian female patients,TNBC is an aggressive subtype of breast cancer that occurs at younger age. Frequently, it is of high grade and presents in an advanced stage.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41654574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-01DOI: 10.21608/RESONCOL.2019.7254.1072
M. Elshenawy, A. Badran, A. Elshentenawy, A. Eldali, M. Memon
Background: Giant-cell tumor of bone (GCTB) is a locally aggressive tumor which metastasizes infrequently to the lungs. The standard treatment of GCTB was surgery until the approval of denosumab. Aim: To describe the outcome of treatment of this rare tumor and to determine factors that influence survival. Methods: Retrospective review of the medical records of GCTB patients treated at our institution. Collected data includes: clinicopathological data, treatment modalities and possible prognostic factors. Results: Forty-two patients were identified between May 2008 and November 2017. Their median age was 31 years, and the majority (62%) were females. The commonest primary sites were the upper and lower limbs (50% and 43%, respectively). Eight (19%) patients initially presented with lung metastases. Thirteen (31%) patients received denosumab as first line treatment before surgery and 12 of them underwent surgery post-denosumab. Denosumab was given after recurrence in 12 (29%) patients [8 (19%) with lung metastasis and 4 (10%) with localized disease]. The objective response rate to denosumab after recurrence was 50%. Four (10%) patients achieved complete response and 2 (5%) partial response. After a median follow up of 4.7 years, 6 (14%) patients had local recurrence and 8 (19%) had lung metastasis with no recorded deaths. The 5-year progression-free survival rate was 61%. Conclusion: Denosumab is effective and tolerable in the management of GCTB preoperatively in localized disease to facilitate surgery and in the management of metastatic disease. Multi-institutional prospective studies are needed for further assessment.
{"title":"Outcome of Treatment of Giant-Cell Tumor of Bone: a Single-Institutional Retrospective Study","authors":"M. Elshenawy, A. Badran, A. Elshentenawy, A. Eldali, M. Memon","doi":"10.21608/RESONCOL.2019.7254.1072","DOIUrl":"https://doi.org/10.21608/RESONCOL.2019.7254.1072","url":null,"abstract":"Background: Giant-cell tumor of bone (GCTB) is a locally aggressive tumor which metastasizes infrequently to the lungs. The standard treatment of GCTB was surgery until the approval of denosumab. Aim: To describe the outcome of treatment of this rare tumor and to determine factors that influence survival. Methods: Retrospective review of the medical records of GCTB patients treated at our institution. Collected data includes: clinicopathological data, treatment modalities and possible prognostic factors. Results: Forty-two patients were identified between May 2008 and November 2017. Their median age was 31 years, and the majority (62%) were females. The commonest primary sites were the upper and lower limbs (50% and 43%, respectively). Eight (19%) patients initially presented with lung metastases. Thirteen (31%) patients received denosumab as first line treatment before surgery and 12 of them underwent surgery post-denosumab. Denosumab was given after recurrence in 12 (29%) patients [8 (19%) with lung metastasis and 4 (10%) with localized disease]. The objective response rate to denosumab after recurrence was 50%. Four (10%) patients achieved complete response and 2 (5%) partial response. After a median follow up of 4.7 years, 6 (14%) patients had local recurrence and 8 (19%) had lung metastasis with no recorded deaths. The 5-year progression-free survival rate was 61%. Conclusion: Denosumab is effective and tolerable in the management of GCTB preoperatively in localized disease to facilitate surgery and in the management of metastatic disease. Multi-institutional prospective studies are needed for further assessment.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41986466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-01DOI: 10.21608/RESONCOL.2019.10154.1074
Abdelhamid M. Fouad, A. Gabal, Mariam Elhaddad
Despite the continuous evolution in different treatment modalities for head and neck cancer (HNC), severe side effects of medications remain a challenge. Chemotherapy (CTH)-induced toxicities may lead to alterations in the treatment plan in the form of dose reduction, treatment delay or even discontinuation of treatment. Many efforts were done to overcome the impact of CTH-induced toxicity on HNC treatment. One of the explored strategies is the pharmacokinetic (PK)-based dosing of CTH. A literature search for trials investigating PK-based CTH dosing in HNC from 1988 to 2018 was performed. Few clinical studies including one randomized clinical trial were identified. The limited evidence obtained from these studies shows that PK-based CTH dosing in HNC results in significantly less toxicities with no detrimental impact on treatment outcome. The current evidence is not enough to recommend the routine use of PK-based CTH dosing in HNC. However, the promising results call for future studies.
{"title":"Pharmacokinetic-Based Chemotherapy Dosing in Advanced Head and Neck Cancer: A Mini Review","authors":"Abdelhamid M. Fouad, A. Gabal, Mariam Elhaddad","doi":"10.21608/RESONCOL.2019.10154.1074","DOIUrl":"https://doi.org/10.21608/RESONCOL.2019.10154.1074","url":null,"abstract":"Despite the continuous evolution in different treatment modalities for head and neck cancer (HNC), severe side effects of medications remain a challenge. Chemotherapy (CTH)-induced toxicities may lead to alterations in the treatment plan in the form of dose reduction, treatment delay or even discontinuation of treatment. Many efforts were done to overcome the impact of CTH-induced toxicity on HNC treatment. One of the explored strategies is the pharmacokinetic (PK)-based dosing of CTH. A literature search for trials investigating PK-based CTH dosing in HNC from 1988 to 2018 was performed. Few clinical studies including one randomized clinical trial were identified. The limited evidence obtained from these studies shows that PK-based CTH dosing in HNC results in significantly less toxicities with no detrimental impact on treatment outcome. The current evidence is not enough to recommend the routine use of PK-based CTH dosing in HNC. However, the promising results call for future studies.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42932635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-02DOI: 10.21608/RESONCOL.2019.6360.1071
M. Moumen, L. E. E. Arab, N. Mosalam, A. Gaballah
Background: Primary brain tumors represent 2% of cancers in adults. Glioblastoma Multiforme (GBM) is the most frequent among these tumors. Different prognostic factors have been identified including age, performance status, extent of surgery and genetic factors. Aim: To analyze treatment outcome and prognostic factors in adult patients with GBM treated at a single institution. Methods: We retrospectively collected the data of patients treated for GBM form January 2012 till December 2016. During this 5-years period, 111 patients were identified and the data of 93(84%) of them was complete and included in the analysis. Results: Males represented 67% of patients, their median age was 52 years and the Eastern Cooperative Oncology Group (ECOG) performance status was 1, 2 and 3 in 48%, 40% and 12% respectively. Only 4.3% of patients underwent complete surgical resection, 38% underwent partial resection and 58% underwent biopsy. Post-operative treatment was radiotherapy alone in 30% of patients and chemo-radiotherapy in 70%. The median progression-free survival (PFS) and overall survival (OS) were 8 months (95% Confidence Interval: 6.678-9.322) and 10 months (95% Confidence Interval: 7.522-12.487), respectively. Longer PFS was associated with age Conclusion: Glioblastoma Multiforme remains an aggressive disease with high mortality rate and poor outcome. Complete resection and adjuvant chemo-radiotherapy improve PFS and OS.
{"title":"Retrospective Analysis of Prognostic Factors in Adult Glioblastoma Multiforme: A Single Institution Experience","authors":"M. Moumen, L. E. E. Arab, N. Mosalam, A. Gaballah","doi":"10.21608/RESONCOL.2019.6360.1071","DOIUrl":"https://doi.org/10.21608/RESONCOL.2019.6360.1071","url":null,"abstract":"Background: Primary brain tumors represent 2% of cancers in adults. Glioblastoma Multiforme (GBM) is the most frequent among these tumors. Different prognostic factors have been identified including age, performance status, extent of surgery and genetic factors. Aim: To analyze treatment outcome and prognostic factors in adult patients with GBM treated at a single institution. Methods: We retrospectively collected the data of patients treated for GBM form January 2012 till December 2016. During this 5-years period, 111 patients were identified and the data of 93(84%) of them was complete and included in the analysis. Results: Males represented 67% of patients, their median age was 52 years and the Eastern Cooperative Oncology Group (ECOG) performance status was 1, 2 and 3 in 48%, 40% and 12% respectively. Only 4.3% of patients underwent complete surgical resection, 38% underwent partial resection and 58% underwent biopsy. Post-operative treatment was radiotherapy alone in 30% of patients and chemo-radiotherapy in 70%. The median progression-free survival (PFS) and overall survival (OS) were 8 months (95% Confidence Interval: 6.678-9.322) and 10 months (95% Confidence Interval: 7.522-12.487), respectively. Longer PFS was associated with age Conclusion: Glioblastoma Multiforme remains an aggressive disease with high mortality rate and poor outcome. Complete resection and adjuvant chemo-radiotherapy improve PFS and OS.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41925498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-02DOI: 10.21608/RESONCOL.2018.6256.1069
H. Elkalla, M. Zahi, Osama Eldamshety
Background: Drug shortages have become a health care problem worldwide. One of the important drugs that are affected by shortage is leucovorin. It is used with 5-fluorouracil in many protocols for gastro-intestinal tumors and its shortage would have a negative impact on the treatment outcome. Aim: To compare the effect of low-dose leucovorin versus the standard-dose in the treatment of stage II and III colon cancer. Methods: The study included 100 patients with stage II or III adenocarcinoma of the colon who presented to the Clinical Oncology Department at Mansoura University Hospital from January 2011 till December 2012 after curative resection and were scheduled to receive adjuvant FOLFOX6 regimen. Patients were randomly allocated to receive standard-dose leucovorin (200 mg/m2, group 1) or low-dose leucovorin (125 mg/m2, group 2), both administered on days 1 and 2 over 2 hours infusion before 5-fluoruracil. The end points were toxicity, disease free survival (DFS) and overall survival (OS). Results: The two study groups were matched regarding age, sex, and tumor stage. The mean DFS was 48.36 months for group 1 and 49.12 for group 2 with no significant difference (p=0.866). The mean OS was 65.07 months for group 1 and 62.45 for group 2 with no significant difference (p=0.544). Similarly, there was no significant difference between the two groups regarding hematosuppression, diarrhea, mucositis, neurotoxicity and the need for hospitalization. Conclusion: Both protocols were well tolerated by all patients with no significant difference in the treatment outcome. The use of low-dose leucovorin protocol can help in solving the leucovorin shortage problem.
{"title":"Low-dose versus Standard-Dose Leucovorin in the Treatment of Colon Cancer: Mansoura University Clinical Experience in Facing the Problem of Leucovorin Shortage","authors":"H. Elkalla, M. Zahi, Osama Eldamshety","doi":"10.21608/RESONCOL.2018.6256.1069","DOIUrl":"https://doi.org/10.21608/RESONCOL.2018.6256.1069","url":null,"abstract":"Background: Drug shortages have become a health care problem worldwide. One of the important drugs that are affected by shortage is leucovorin. It is used with 5-fluorouracil in many protocols for gastro-intestinal tumors and its shortage would have a negative impact on the treatment outcome. Aim: To compare the effect of low-dose leucovorin versus the standard-dose in the treatment of stage II and III colon cancer. Methods: The study included 100 patients with stage II or III adenocarcinoma of the colon who presented to the Clinical Oncology Department at Mansoura University Hospital from January 2011 till December 2012 after curative resection and were scheduled to receive adjuvant FOLFOX6 regimen. Patients were randomly allocated to receive standard-dose leucovorin (200 mg/m2, group 1) or low-dose leucovorin (125 mg/m2, group 2), both administered on days 1 and 2 over 2 hours infusion before 5-fluoruracil. The end points were toxicity, disease free survival (DFS) and overall survival (OS). Results: The two study groups were matched regarding age, sex, and tumor stage. The mean DFS was 48.36 months for group 1 and 49.12 for group 2 with no significant difference (p=0.866). The mean OS was 65.07 months for group 1 and 62.45 for group 2 with no significant difference (p=0.544). Similarly, there was no significant difference between the two groups regarding hematosuppression, diarrhea, mucositis, neurotoxicity and the need for hospitalization. Conclusion: Both protocols were well tolerated by all patients with no significant difference in the treatment outcome. The use of low-dose leucovorin protocol can help in solving the leucovorin shortage problem.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44894096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-19DOI: 10.21608/RESONCOL.2018.3478.1056
R. Ghali, D. Boulos, M. Alorabi
Background: Oncologists are at risk of developing burn out syndrome due to many stressors they may face. Aim: To determine the level of burnout in a cohort of clinical oncologists working in an Egyptian university hospital. Methods: Fifty-two clinical oncologists were invited to participate in the study. Burnout was assessed using the Arabic version of Maslach Burnout Inventory Human Services Survey (MBI-HSS).Results: The response rate was 90% (47/52). The majority (70%) of responders were young oncologists and 62% had >10 years experience in the oncology field. Females represented 52% of them and 62% were married. The MBI-HSS scores indicated that 72% of participants had burnout on the emotional exhaustion (EE) scale, 49% on the depersonalization (DP) scale and 38% on the personal accomplishment (PA) scale. A significantly lower PA score was associated with female gender, being single, viewing vacation time as insufficient, and an experience duration <10 years in oncology (p = 0.01, 0.01, 0.03, and 0.02; respectively). The preference not to choose again oncology as a career was also associated with significantly lower PA score and higher EE score (p=0.02 and 0.001; respectively). Conclusion: The surveyed oncologists experienced high burnout. Larger studies are needed in order to assess the burden of the problem and to develop evidence-based interventions to reduce it.
{"title":"Cross-Sectional Study of Burnout among a Group of Egyptian Oncologists at Ain Shams University","authors":"R. Ghali, D. Boulos, M. Alorabi","doi":"10.21608/RESONCOL.2018.3478.1056","DOIUrl":"https://doi.org/10.21608/RESONCOL.2018.3478.1056","url":null,"abstract":"Background: Oncologists are at risk of developing burn out syndrome due to many stressors they may face. Aim: To determine the level of burnout in a cohort of clinical oncologists working in an Egyptian university hospital. Methods: Fifty-two clinical oncologists were invited to participate in the study. Burnout was assessed using the Arabic version of Maslach Burnout Inventory Human Services Survey (MBI-HSS).Results: The response rate was 90% (47/52). The majority (70%) of responders were young oncologists and 62% had >10 years experience in the oncology field. Females represented 52% of them and 62% were married. The MBI-HSS scores indicated that 72% of participants had burnout on the emotional exhaustion (EE) scale, 49% on the depersonalization (DP) scale and 38% on the personal accomplishment (PA) scale. A significantly lower PA score was associated with female gender, being single, viewing vacation time as insufficient, and an experience duration <10 years in oncology (p = 0.01, 0.01, 0.03, and 0.02; respectively). The preference not to choose again oncology as a career was also associated with significantly lower PA score and higher EE score (p=0.02 and 0.001; respectively). Conclusion: The surveyed oncologists experienced high burnout. Larger studies are needed in order to assess the burden of the problem and to develop evidence-based interventions to reduce it.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47338314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-08DOI: 10.21608/RESONCOL.2018.6131.1067
N. Bary, M. Maher, Mohamed M Elsherbini, M. Abdeen, T. Hashem
This corrigendum corrects the author list and affiliations of the article: Abd El Bary et al. Cost Effectiveness Analysis of Letrozole Compared with Tamoxifen as Initial Adjuvant Therapy for Postmenopausal Women with Endocrine Responsive Breast Cancer. Kasr El-Aini J Clin Oncol Nucl Med. 2009; 5(3-4): 11-17.In response to a request supported by documents from the corresponding author, the name Dr. Mohamed Elsherbini was added to the list of authors and the affiliation of Dr. Mohamed Abdeen was mentioned.The corrected version of this article replaces the primarily published one.
本更正更正了这篇文章的作者名单和隶属关系：Abd El Bary等人。来曲唑与三苯氧胺作为内分泌反应性癌症绝经后妇女初始辅助治疗的成本效益分析。Kasr El Aini临床肿瘤学杂志，2009；5（3-4）：11-17根据通讯作者的文件支持的请求，Mohamed Elsherbini博士被添加到作者名单中，并提到Mohamed Abdeen博士的隶属关系。这篇文章的更正版本取代了最初发表的版本。
{"title":"Corrigendum: Abd El Bary et al. Cost Effectiveness Analysis of Letrozole Compared with Tamoxifen as Initial Adjuvant Therapy for Postmenopausal Women with Endocrine Responsive Breast Cancer. Kasr El-Aini J Clin Oncol Nucl Med. 2009; 5(3-4): 11-17.","authors":"N. Bary, M. Maher, Mohamed M Elsherbini, M. Abdeen, T. Hashem","doi":"10.21608/RESONCOL.2018.6131.1067","DOIUrl":"https://doi.org/10.21608/RESONCOL.2018.6131.1067","url":null,"abstract":"This corrigendum corrects the author list and affiliations of the article: Abd El Bary et al. Cost Effectiveness Analysis of Letrozole Compared with Tamoxifen as Initial Adjuvant Therapy for Postmenopausal Women with Endocrine Responsive Breast Cancer. Kasr El-Aini J Clin Oncol Nucl Med. 2009; 5(3-4): 11-17.In response to a request supported by documents from the corresponding author, the name Dr. Mohamed Elsherbini was added to the list of authors and the affiliation of Dr. Mohamed Abdeen was mentioned.The corrected version of this article replaces the primarily published one.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":"45 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41283553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：